Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Terminated 2

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2729Lung Neoplasms 945Small Cell Lung Carcinoma 447Neoplasms 419Colorectal Neoplasms 409Breast Neoplasms 355Melanoma 332Ovarian Neoplasms 316Neoplasm Metastasis 281Pancreatic Neoplasms 252Squamous Cell Carcinoma of Head and Neck 232Stomach Neoplasms 227Carcinoma, Renal Cell 214Triple Negative Breast Neoplasms 190Head and Neck Neoplasms 178Prostatic Neoplasms 152Esophageal Neoplasms 149Endometrial Neoplasms 145Uterine Cervical Neoplasms 139Urinary Bladder Neoplasms 132Mesothelioma 115Carcinoma 106Colonic Neoplasms 104Carcinoma, Hepatocellular 104Sarcoma 99Carcinoma, Transitional Cell 99Kidney Neoplasms 74Mesothelioma, Malignant 72Cholangiocarcinoma 67Liver Neoplasms 66

Interventions

famitinib 1camrelizumab 1aflutinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced NSCLC × Thoracic × Clear all
NCT03127449 2025-04-03

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Allist Pharmaceuticals, Inc.

Phase NA Terminated
116 enrolled
Thoracic

Advanced NSCLC

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
1 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡